Androgen-regulated expression of arginase 1, arginase 2 and interleukin-8 in human prostate cancer

PLoS ONE

Volumn 5, Issue 8, 2010, Pages

  Gannon, Philippe O ^a   Godin Ethier, Jessica ^a   Hassler, Matthew ^b   Delvoye, Nathalie ^a   Aversa, Meghan ^a   Poisson, Alexis O ^a   Péant, Benjamin ^a   Fahmy, Mona Alam ^a   Saad, Fred ^a   Lapointe, Réjean ^a,c   Mes Masson, Anne Marie ^a,c  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANTIANDROGEN; ARGINASE; ARGINASE 1; ARGINASE 2; ARGININE; INTERLEUKIN 8; MESSENGER RNA; METRIBOLONE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

AMINO ACID METABOLISM; ARTICLE; CANCER CELL CULTURE; CANCER TISSUE; CELL ACTIVATION; CELL STIMULATION; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GROWTH INHIBITION; HORMONAL REGULATION; HORMONE RESISTANCE; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE DEFICIENCY; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RNA INTERFERENCE; CASE CONTROL STUDY; GENETICS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; METABOLISM; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ANDROGENS; ARGINASE; CASE-CONTROL STUDIES; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNE TOLERANCE; INTERLEUKIN-8; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 77957881272     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012107     Document Type: Article

References (43)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2008) Cancer statistics, 2008. CA Cancer J Clin 58: 71-96.
2. Grossmann ME, Huang H, Tindall DJ (2001) Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 93: 1687-1697.
3. Montironi R, Schulman CC (1998) Pathological changes in prostate lesions after androgen manipulation. J Clin Pathol 51: 5-12.
4. Chang SS, Kibel AS (2009) The role of systemic cytotoxic therapy for prostate cancer. BJU Int 103: 8-17.
5. Miller AM, Pisa P (2007) Tumor escape mechanisms in prostate cancer. Cancer Immunol Immunother 56: 81-87.
6. Mumenthaler SM, Yu H, Tze S, Cederbaum SD, Pegg AE, et al. (2008) Expression of arginase II in prostate cancer. Int J Oncol 32: 357-365.
7. Bronte V, Kasic T, Gri G, Gallana K, Borsellino G, et al. (2005) Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med 201: 1257-1268.
8. Bronte V, Zanovello P (2005) Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 5: 641-654.
9. Mercader M, Bodner BK, Moser MT, Kwon PS, Park ES, et al. (2001) T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A 98: 14565-14570.
10. Gannon PO, Poisson AO, Delvoye N, Lapointe R, Mes-Masson AM, et al. (2009) Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods 348: 9-17.
11. Yamanaka H, Kirdani RY, Saroff J, Murphy GP, Sandberg AA (1975) Effects of testosterone and prolactin on rat prostatic weight, 5alpha-reductase, and arginase. Am J Physiol 229: 1102-1109.
12. Manteuffel-Cymborowska M, Chmurzynska W, Peska M, Grzelakowska-Sztabert B (1995) Arginine and ornithine metabolizing enzymes in testosterone- induced hypertrophic mouse kidney. Int J Biochem Cell Biol 27: 287-295.
13. Levillain O, Diaz JJ, Blanchard O, Dechaud H (2005) Testosterone downregulates ornithine aminotransferase gene and up-regulates arginase II and ornithine decarboxylase genes for polyamines synthesis in the murine kidney. Endocrinology 146: 950-959.
14. Lu S, Wang A, Dong Z (2007) A novel synthetic compound that interrupts androgen receptor signaling in human prostate cancer cells. Mol Cancer Ther 6: 2057-2064.
15. Munder M (2009) Arginase: an emerging key player in the mammalian immune system. Br J Pharmacol 158: 638-651.
16. Munder M, Eichmann K, Moran JM, Centeno F, Soler G, et al. (1999) Th1/ Th2-regulated expression of arginase isoforms in murine macrophages and dendritic cells. J Immunol 163: 3771-3777.
17. Seaton A, Scullin P, Maxwell PJ, Wilson C, Pettigrew J, et al. (2008) Interleukin- 8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation. Carcinogenesis 29: 1148-1156.
18. Lin MF, Lee MS, Garcia-Arenas R, Lin FF (2000) Differential responsiveness of prostatic acid phosphatase and prostate-specific antigen mRNA to androgen in prostate cancer cells. Cell Biol Int 24: 681-689.
19. Mumenthaler SM, Rozengurt N, Livesay JC, Sabaghian A, Cederbaum SD, et al. (2008) Disruption of arginase II alters prostate tumor formation in TRAMP mice. Prostate.
20. Kee K, Vujcic S, Merali S, Diegelman P, Kisiel N, et al. (2004) Metabolic and antiproliferative consequences of activated polyamine catabolism in LNCaP prostate carcinoma cells. J Biol Chem 279: 27050-27058.
21. Xu Q, Baker BS, Tata JR (1993) Developmental and hormonal regulation of the Xenopus liver-type arginase gene. Eur J Biochem 211: 891-898.
22. Olszewska A, Krol K, Weglenski P, Dzikowska A (2007) Arginine catabolism in Aspergillus nidulans is regulated by the rrmA gene coding for the RNA-binding protein. Fungal Genet Biol 44: 1285-1297.
23. Harris BE, Pretlow TP, Bradley EL, Jr., Whitehurst GB, Pretlow TG, 2nd (1983) Arginase activity in prostatic tissue of patients with benign prostatic hyperplasia and prostatic carcinoma. Cancer Res 43: 3008-3012.
24. Keskinege A, Elgun S, Yilmaz E (2001) Possible implications of arginase and diamine oxidase in prostatic carcinoma. Cancer Detect Prev 25: 76-79.
25. Pretlow TG, 2nd, Harris BE, Bradley EL, Jr., Bueschen AJ, Lloyd KL, et al. (1985) Enzyme activities in prostatic carcinoma related to Gleason grades. Cancer Res 45: 442-446.
26. Singh R, Pervin S, Karimi A, Cederbaum S, Chaudhuri G (2000) Arginase activity in human breast cancer cell lines: N(omega)-hydroxy-L-arginine selectively inhibits cell proliferation and induces apoptosis in MDA-MB-468 cells. Cancer Res 60: 3305-3312.
27. Buga GM, Wei LH, Bauer PM, Fukuto JM, Ignarro LJ (1998) NG-hydroxy-Larginine and nitric oxide inhibit Caco-2 tumor cell proliferation by distinct mechanisms. Am J Physiol 275: R1256-1264.
28. Tate DJ, Jr., Vonderhaar DJ, Caldas YA, Metoyer T, Patterson JRt, et al. (2008) Effect of arginase II on L-arginine depletion and cell growth in murine cell lines of renal cell carcinoma. J Hematol Oncol 1: 14.
29. Brat DJ, Bellail AC, Van Meir EG (2005) The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro Oncol 7: 122-133.
30. Araki S, Omori Y, Lyn D, Singh RK, Meinbach DM, et al. (2007) Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Res 67: 6854-6862.
31. Murphy C, McGurk M, Pettigrew J, Santinelli A, Mazzucchelli R, et al. (2005) Nonapical and cytoplasmic expression of interleukin-8, CXCR1, and CXCR2 correlates with cell proliferation and microvessel density in prostate cancer. Clin Cancer Res 11: 4117-4127.
32. Lessard L, Saad F, Le Page C, Diallo JS, Peant B, et al. (2007) NF-kappaB2 processing and p52 nuclear accumulation after androgenic stimulation of LNCaP prostate cancer cells. Cell Signal 19: 1093-1100.
33. Diallo JS, Betton B, Parent N, Peant B, Lessard L, et al. (2008) Enhanced killing of androgen-independent prostate cancer cells using inositol hexakisphosphate in combination with proteasome inhibitors. Br J Cancer 99: 1613-1622.
34. Pfaffl MW (2001) A new mathematical model for relative quantification in realtime RT-PCR. Nucleic Acids Res 29: e45.
35. Le Page C, Koumakpayi IH, Lessard L, Saad F, Mes-Masson AM (2005) Independent role of phosphoinositol-3-kinase (PI3K) and casein kinase II (CK-2) in EGFR and Her-2-mediated constitutive NF-kappaB activation in prostate cancer cells. Prostate 65: 306-315.
36. Grandvaux N, Gaboriau F, Harris J, tenOever BR, Lin R, et al. (2005) Regulation of arginase II by interferon regulatory factor 3 and the involvement of polyamines in the antiviral response. FEBS J 272: 3120-3131.
37. Le Page C, Koumakpayi IH, Alam-Fahmy M, Mes-Masson AM, Saad F (2006) Expression and localisation of Akt-1, Akt-2 and Akt-3 correlate with clinical outcome of prostate cancer patients. Br J Cancer 94: 1906-1912.
38. Diallo JS, Aldejmah A, Mouhim AF, Peant B, Fahmy MA, et al. (2007) NOXA and PUMA expression add to clinical markers in predicting biochemical recurrence of prostate cancer patients in a survival tree model. Clin Cancer Res 13: 7044-7052.
39. Gannon PO, Koumakpayi IH, Le Page C, Karakiewicz PI, Mes-Masson AM, et al. (2008) Ebp1 expression in benign and malignant prostate. Cancer Cell Int 8: 18.
40. Koumakpayi IH, Diallo JS, Le Page C, Lessard L, Gleave M, et al. (2006) Expression and nuclear localization of ErbB3 in prostate cancer. Clin Cancer Res 12: 2730-2737.
41. Gannon PO, Alam Fahmy M, Begin LR, Djoukhadjian A, Filali-Mouhim A, et al. (2006) Presence of prostate cancer metastasis correlates with lower lymph node reactivity. Prostate 66: 1710-1720.
42. Gopalakrishnan V, Burton PJ, Blaschke TF (1996) High-performance liquid chromatographic assay for the quantitation of L-arginine in human plasma. Anal Chem 68: 3520-3523.
43. Godin-Ethier J, Pelletier S, Hanafi LA, Gannon PO, Forget MA, et al. (2009) Human activated T lymphocytes modulate IDO expression in tumors through Th1/Th2 balance. J Immunol 183: 7752-7760.